Perfil da empresa · Healthcare

Becton Dickinson and Company

BDX · EUA
Indústria
Medical Devices
Bolsa
EUA
País / Região
USA
Data do IPO
1 de janeiro de 1987
Funcionários
60.000
Preço atual
$143.98
Ao vivo · 18 de junho de 2026
Pontuação de Crescimento Baillie
40/100
Fraco
Valor intrínseco · Faixa em três níveis Preço atual $143.98 Ao vivo · Entre as faixas conservadora e justa

Faixa de valuation composta · conservador $108–$125 / justo $154–$178 / otimista $217–$249. A $143.98, Entre as faixas conservadora e justa.

Na publicação $147.63 (24 de maio de 2026)

Ainda não há análises sobre este ativo no seu idioma.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care

Valor de mercadoUS$ 39,02 bi
Receita (TTM)US$ 22,23 bi
EBITDAUS$ 6,16 bi
Margem líquida5,12%
ROE6,67%
P/L (TTM)24,71
P/L projetado10,49
PEG1,11
LPAUS$ 5,73
Dividend yield2,88%
Faixa de 52 semanasUS$ 125,21 – US$ 184,86
Preço-alvo dos analistasUS$ 180,69
Recomendação dos analistas3.8 / 5

Dados da EODHD, apresentados na moeda de reporte; apenas para referência, não constitui recomendação de investimento.

História

Em breveEsta seção está sendo preenchida — volte em breve.

Posição no setor

Em breveEsta seção está sendo preenchida — volte em breve.